Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study

Féline E V Scheijmans; Inge Cuppen; Ruben P A van Eijk; Camiel A Wijngaarde; Marja A G C Schoenmakers; Danny R van der Woude; Bart Bartels; Esther S Veldhoen; Irene L B Oude Lansink; Ewout J N Groen; Fay-Lynn Asselman; Renske I Wadman; W Ludo van der Pol

doi:10.1093/braincomms/fcac269

Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study

Brain Commun. 2022 Oct 31;4(6):fcac269. doi: 10.1093/braincomms/fcac269. eCollection 2022.

Affiliations

¹ Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
² Biostatistics and Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, 3584 CX, Utrecht, The Netherlands.
³ Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.
⁴ Pediatric Intensive Care Unit, Wilhelmina Children's Hospital, 3584 EA, Utrecht, The Netherlands.
⁵ Department of Rehabilitation, Physical Therapy Science and Sports, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands.

Abstract

Nusinersen (Spinraza®) improves survival of infants with hereditary proximal spinal muscular atrophy and motor function in children up to 12 years. Population-based assessments of treatment efficacy are limited and confined to select cohorts of patients. We performed a nationwide, population-based, single-centre cohort study in children with spinal muscular atrophy younger than 9.5 years at start of treatment in line with reimbursement criteria in the Netherlands. We assessed age-relevant motor function scores, the need for tube feeding, hours of ventilatory support and documented adverse events. We used linear mixed modelling to assess treatment effects. We compared motor function during treatment with natural history data and to individual trajectories of muscle strength and motor function before the start of treatment. We included 71 out of 72 Dutch children who were treated (median age 54 months; range 0-117) and followed them for a median of 38 months (range 5-52). We observed improvement of motor function in 72% and stabilization in another 18% of the symptomatic children, which differed from the natural disease course in a matched cohort of which we had previously collected natural history data. Longitudinal analysis showed that motor function improved up to a median of 24 months (range 12-30) of treatment after which it stabilized. Shorter disease duration at start of treatment resulted in better treatment efficacy (P < 0.01). Sixteen children (23%) achieved new motor milestones. Bulbar and respiratory function did not improve significantly during treatment. In 15 patients from whom treatment-naïve data were available, the pre-treatment trajectory of motor function decline changed to stabilization or improvement after the start of treatment. We documented 82 adverse events after 934 injections (9%) in 45 patients. None of the adverse events led to treatment discontinuation. Intrathecal nusinersen treatment is safe and improves or stabilizes motor function in 90% of young children with spinal muscular atrophy types 1c-3a. We did not observe improvement of respiratory and bulbar functions.

Keywords: children; motor function; nusinersen; spinal muscular atrophy; treatment.